| Jun 28 |
Eisai and Biogen launch Alzheimer's drug Leqembi in China
|
| Jun 27 |
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
|
| Jun 26 |
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
|
| Jun 26 |
Pharma M&A: The top high value deals in 2023
|
| Jun 25 |
Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?
|
| Jun 24 |
Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy?
|
| Jun 24 |
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
|
| Jun 19 |
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
| Jun 17 |
Two Is Better Than One in the Alzheimer’s Market
|
| Jun 17 |
ALS pipeline suffers a major hit as Biogen’s Tofersen fails phase iii trial
|
